Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

Phase 3 Recruiting 80 enrolled The Cleveland Clinic Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.

Timeline

Start: 2024-06-01
Primary completion: 2026-10-31
Completion: 2026-12-31

Publications

Background Cotton PB. Are low-volume ERCPists a problem in the United States? A plea to examine and improve ERCP practice-NOW. Gastrointest Endosc. 2011 Jul;74(1):161-6. doi: 10.1016/j.gie.2011.03.1233. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Neostigmine	Other / unclassified	0.07 mg/kg	—
Subject	Sugammadex	Other / unclassified	2 mg/kg	—

Indications

No indication recorded.